Biosimilars are, as the name would suggest, highly similar and are a more affordable alternative to biologics that is poised to influence the current dynamics of the immunology market. ...Read More
Sandoz, a Novartis division, recently announced that The Canadian Drug Expert Committee (CDEC) as part of the Common Drug Review (CDR) process has issued a positive drug reimbursement recommendation f...Read More
